Government-owned miniratna company MOIL has signed a Memorandum of Understanding (MoU) with the Ministry of Steel, India and where it has set a production target of 14.75 lac tonnes of manganese ore for FY20E.

Zuari Agro Chemicals on Thursday informed the bourses that, rating agency ICRA has downgraded its short term and long-term funds worth Rs. 4215 crore. The long-term rating was downgraded to D from BB (Negative) earlier. While short-term also downgraded to D from A4.

JMC Projects India Limited has bagged new orders worth Rs. 616 crores. The orders include residential and commercial projects in South India.

The software major has completed the acquisition of 75 per cent stake in ABN AMRO subsidiary in the Netherlands. The partnership will strengthen Infosys' business process management solutions in the mortgage services value chain in Europe.

Overall volumes in futures & options currently stand at 3,66,71,127 contracts with a turnover of Rs.25,81,257.90 crore.

Overall volumes in futures & options currently stand at 3,66,71,127 contracts with a turnover of Rs.25,81,257.90 crore.

The Monday session low of 11,592 is the key support level and if Nifty fails to hold this support level, it will fill the gap of May 20. On the higher side now, the zone of 11,820-11,850 is likely to act as a critical resistance for further upmove. Stocks in news: Infosys, MOIL, CIPLA, Greaves Cotton, Reliance Nippon Life Asset Management, Radico Khaitan, Om Metal Infraprojects, Zensar Technologies.

Despite the global markets remaining vulnerable by amplified pessimism regarding a solution to the US-China trade war, the Indian markets are expected to open the session on a positive note. At the time of writing, the SGX Nifty was trading higher by 55 points at 11,734. The quarterly numbers on tap are Bata India, Dish TV, Heidelberg, IDFC, IGL, JSW Steel, NCC and REC.

ADAG groups, Reliance Nippon made a public announcement that Nippon Life Insurance of Japan has signed binding definitive agreements with Reliance Capital Limited to increase its stake in the company.

Suven Life Sciences Limited has informed the bourses that the last patient has completed his last visit for the Phase 2 POC study of SUVN-502 for moderate Alzheimer’s disease. This is the first-ever study to evaluate a triple combination therapy for moderate Alzheimer’s disease patients.